Status:
COMPLETED
RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.
Lead Sponsor:
Pfizer
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This is a retrospective, observational study that will document treatment patterns and clinical outcomes of postmenopausal patients diagnosed with HR+/HER2- mBC who received Palbociclib plus Letrozole...
Eligibility Criteria
Inclusion
- Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
- Diagnosed with locoregional recurrent or metastatic female breast cancer.
- Pathologically confirmed HR-positive/HER2-negative diagnosis.
- Received treatment with palbociclib in combination with letrozole as initial endocrine-based therapy for advanced/metastatic breast cancer:
- Initiated treatment with palbociclib at least 3 months following the provider's first use of palbociclib following its FDA approval.
- At least 1 month of follow-up (at least one visit with the provider) after initiation of palbociclib.
- Postmenopausal (or receiving surgical or medical treatment to induce menopause) at the time of initiation of palbociclib.
- ≥18 year old at initiation of palbociclib.
Exclusion
- No exclusion criteria will be imposed for the selection of patients.
Key Trial Info
Start Date :
January 4 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 24 2019
Estimated Enrollment :
195 Patients enrolled
Trial Details
Trial ID
NCT04460898
Start Date
January 4 2019
End Date
June 24 2019
Last Update
October 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer United States
New York, New York, United States, 10017